{"id":2338,"date":"2025-09-15T16:23:45","date_gmt":"2025-09-15T09:23:45","guid":{"rendered":"https:\/\/productregistrationindonesia.com\/?p=2338"},"modified":"2025-12-10T22:12:15","modified_gmt":"2025-12-10T15:12:15","slug":"us-medical-device-success-in-indonesia-regulatory-strategy-the-product-registration-indonesia-website","status":"publish","type":"post","link":"https:\/\/stage-main-2025.productregistrationindonesia.com\/id\/us-medical-device-success-in-indonesia-regulatory-strategy-the-product-registration-indonesia-website\/","title":{"rendered":"Keberhasilan Alat Kesehatan AS di Indonesia: Strategi Regulasi & Situs Web Registrasi Produk Indonesia"},"content":{"rendered":"\n

Indonesia\u2019s healthcare market is rapidly expanding, and American medtech firms are moving in. In fact, Indonesia\u2019s fourth-largest population has prompted healthcare reforms<\/strong> that greatly increase demand for modern devices. The U.S. Embassy notes that \u201cAmerican medical devices, diagnostic equipment, and medicines are helping healthcare providers deliver the best care possible\u201d in Indonesia[1]<\/a>. However, success requires navigating complex regulations and mastering the Indonesian Ministry of Health\u2019s online registration system \u2013 the MoH \u201cRegalkes\u201d portal, often called the product registration Indonesia website<\/strong> \u2013 to gain timely market access.<\/p>\n\n\n\n

Indonesia\u2019s Regulatory Framework and the MoH Portal<\/h1>\n\n\n\n

Medical devices in Indonesia are regulated by the Ministry of Health (MoH). Under MoH Regulation No. 62\/2017, every device must obtain a Nomor Izin Edar (NIE)<\/strong> registration number before import or sale[2]<\/a>. Registrations follow the ASEAN Common Submission Dossier Template (CSDT), meaning companies should prepare dossiers in the standardized ASEAN format[3]<\/a>. In practice, having FDA clearance or CE marking is helpful but not sufficient<\/strong> \u2013 the Indonesian guidelines require translation of all labels and Instructions for Use into Bahasa Indonesia, notarization of foreign certificates (e.g. Certificate of Free Sale, GMP, or Letter of Authorization), and submission of localized technical files[4]<\/a>. In short, U.S. firms must adapt global documentation to Indonesian rules.<\/p>\n\n\n\n

The Ministry of Health\u2019s online Regalkes portal is the core digital platform for all medical device registrations<\/em>[5]<\/em><\/a>.<\/em> All submissions, fees, and correspondence are handled through the Regalkes system. The Regalkes portal (regalkes.kemkes.go.id) provides a structured workflow: companies upload dossiers<\/strong>, respond to MoH clarification requests, and receive NIE approvals online[5]<\/a>[6]<\/a>. Because the interface is in Bahasa Indonesia and has strict naming conventions, many U.S. firms work closely with local regulatory consultants. Indeed, step-by-step guides on sites like ProductRegistrationIndonesia.com explain how to navigate this product registration Indonesia website<\/strong> end-to-end[2]<\/a>. In practice, a foreign manufacturer must appoint a local representative (with a valid Izin Distribusi Alat Kesehatan, or IDAK license), supply an embassy-legalized Letter of Authorization and Certificate of Free Sale, and ensure the local distributor holds the required Good Distribution Practice certificate (CDAKB)[7]<\/a>[8]<\/a>. Notably, as of July 2024 the MoH enforces CDAKB certification \u2013 distributors cannot<\/strong> complete a new device registration without it[7]<\/a>.<\/p>\n\n\n\n

Leveraging Regulatory Intelligence<\/h1>\n\n\n\n

Regulatory expertise and intelligence<\/strong> are key for U.S. companies. One advantage is leveraging existing approvals. For example, under recent trade commitments Indonesia agreed to accept U.S. FDA certificates and prior authorizations<\/strong> for medical devices[9]<\/a>. In practice, this means a firm can include its FDA 510(k) or PMA documentation in the Regalkes dossier, then supplement with the ASEAN CSDT structure. Indeed, Indonesia\u2019s guidelines align with the ASEAN Medical Device Directive, but still require local translations and adaptations[3]<\/a>. By preparing dossiers in advance according to ASEAN CSDT and having CE\/FDA docs ready to legalize, companies avoid redundant testing and shorten review times.<\/p>\n\n\n\n

Another example of regulatory intelligence is monitoring Indonesia\u2019s TKDN (local content)<\/strong> policies. Indonesian law often favors products with high Domestic Component Level (TKDN). However, bilateral agreements have begun to ease these requirements for U.S. imports. In mid-2025, Coordinating Minister Airlangga Hartarto announced that certain U.S. medical device components will be exempted from TKDN rules<\/strong>[10]<\/a>. In plain terms, select American-made medical products can bypass strict local content quotas when registering in Indonesia, provided they meet other regulatory requirements (such as MoH safety standards). This reflects a broader shift \u2013 during the COVID-19 emergency, Indonesia accelerated approvals for U.S. products by accepting FDA and WHO\/USP certifications (e.g. AstraZeneca and Pfizer vaccines were approved based on FDA and WHO data[11]<\/a>).<\/p>\n\n\n\n

Likewise, savvy firms ensure compliance with Indonesia\u2019s new distribution rules<\/strong>. The MoH now requires distributors to obtain an official Good Distribution Practice (CDAKB) certificate before any device can be registered[7]<\/a>. In practical terms, U.S. exporters should vet their Indonesian partners for CDAKB and IDAK licenses up front. They should also prepare quality control and packaging procedures to satisfy Indonesian standards. Consulting the detailed checklists on resources like ProductRegistrationIndonesia.com helps ensure no paperwork gaps[7]<\/a>[8]<\/a>.<\/p>\n\n\n\n

Impact of U.S.\u2013Indonesia Trade Policies<\/h1>\n\n\n\n

Recent U.S. trade policies have significantly affected market access for medical equipment. In 2025 the Trump administration announced a \u201creciprocal trade deal\u201d whereby the U.S. would impose a flat 19% tariff on Indonesian exports while eliminating tariffs on nearly all U.S. exports to Indonesia<\/strong>[12]<\/a>[13]<\/a>. President Trump himself declared that under the agreement \u201cThey are going to pay 19% and we are going to pay nothing \u2013 we will have full access into Indonesia<\/em>\u201d[13]<\/a>. In other words, American-made medical devices now effectively enter Indonesia tariff-free<\/strong> under this deal. Official fact sheets confirm Indonesia will remove tariff barriers on over 99% of U.S. products, explicitly including health and medical products[12]<\/a>.<\/p>\n\n\n\n

These trade moves also targeted non-tariff hurdles. The U.S. extract of the agreement states that Indonesia agreed to accept FDA certifications and eliminate burdensome labeling requirements on cosmetics and medical devices[9]<\/a>. Likewise, the Indonesian side negotiated the relaxation of its onerous TKDN and import licensing<\/strong> requirements for U.S. goods[10]<\/a>. In tandem, Indonesia\u2019s economic ministers have indicated ongoing negotiations to cut key tariffs \u201cbelow 19% and potentially down to zero\u201d on strategic imports[14]<\/a>.<\/p>\n\n\n\n

Prior to these deals, the Indonesian industry had faced U.S.-imposed tariffs on its exports. Indonesian media point out that under Trump\u2019s previous tariff lists, U.S. duties on Indonesian goods peaked at 32%[15]<\/a> (versus 19% in the new deal). Industry groups warned that U.S. actions specifically cited Indonesia\u2019s TKDN rules as a non-tariff barrier[15]<\/a>. On balance, however, the current bilateral agreement liberates American exporters<\/strong> of medical devices: Indonesian tariffs are gone and regulatory recognition has improved. As one U.S. trade article notes, \u201cIndonesian producers do not have to withstand burdensome new testing for FDA-approved products,\u201d reflecting the new acceptance of U.S. standards[9]<\/a>[13]<\/a>.<\/p>\n\n\n\n

Case Study: U.S.\u2013Indonesia CT Scanner Collaboration<\/h1>\n\n\n\n

A concrete success story is the U.S. firm GE Healthcare partnering locally. In June 2025 GE HealthCare<\/strong>, in collaboration with Indonesian pharmaceutical giant PT Kalbe Farma, opened Indonesia\u2019s first CT scanner assembly plant<\/em>[16]<\/a>. The Bogor-based facility allows GE to assemble advanced CT diagnostic machines locally, meeting Jakarta\u2019s push for domestic production of key medical devices. GE\u2019s CEO stated the new plant \u201cwill help us respond faster to local needs while maintaining the highest international standards of quality and safety\u201d[17]<\/a>. Kalbe\u2019s management highlighted that the joint venture supports Indonesia\u2019s national health resilience and reduces dependence on imports[17]<\/a>. The facility is expected to \u201creduce reliance on imports, shorten delivery times, and support job creation\u201d while boosting local tech capabilities[17]<\/a>. Indonesian press confirms the investment (about IDR 260 billion) and notes that GE engineers will train local workers in CT scan assembly[18]<\/a>.<\/p>\n\n\n\n

Beyond GE, many major U.S. medical technology players have a growing presence. For example, U.S.-origin devices already account for roughly 10% of Indonesia\u2019s medical imports<\/strong>[19]<\/a>. Global leaders like Medtronic, Becton Dickinson, Abbott, and Johnson & Johnson supply advanced equipment to Indonesian hospitals, and have long-term distributors in Jakarta and regional offices. These companies have gradually expanded by engaging local partners to meet Indonesian rules. The GE\/Kalbe CT project exemplifies the kind of joint venture that adapts to Indonesia\u2019s Domestic Component (TKDN) policy while bringing U.S. innovation onshore[16]<\/a>[20]<\/a>.<\/p>\n\n\n\n

Strategic Tips for U.S. Companies Entering Indonesia<\/h1>\n\n\n\n